TY - JOUR
T1 - Developing proteomic biomarkers for bladder cancer: Towards clinical application
AU - Frantzi, Maria
AU - Latosinska, Agnieszka
AU - Flühe, Leif
AU - Hupe, Marie C.
AU - Critselis, Elena
AU - Kramer, Mario W.
AU - Merseburger, Axel S.
AU - Mischak, Harald
AU - Vlahou, Antonia
PY - 2015/6/12
Y1 - 2015/6/12
N2 - Clinical use of proteomic biomarkers has the potential to substantially improve the outcomes of patients with bladder cancer. An unmet clinical need evidently exists for noninvasive biomarkers, which might enable improvements in both the diagnosis and prognosis of patients with bladder cancer, as well as improved monitoring of patients for the presence of recurrence. Urine is considered the optimal noninvasive source of proteomic biomarkers in patients with bladder cancer. Currently, a number of single-protein biomarkers have been detected in urine and tissue using a variety of proteomic techniques, each having specific conceptual considerations and technical implications. Promising preclinical data are available for several of these proteins; however, the combination of single urinary proteins into multimarker panels might better encompass the molecular heterogeneity of bladder cancer within this patient population, and prove more effective in clinical use.
AB - Clinical use of proteomic biomarkers has the potential to substantially improve the outcomes of patients with bladder cancer. An unmet clinical need evidently exists for noninvasive biomarkers, which might enable improvements in both the diagnosis and prognosis of patients with bladder cancer, as well as improved monitoring of patients for the presence of recurrence. Urine is considered the optimal noninvasive source of proteomic biomarkers in patients with bladder cancer. Currently, a number of single-protein biomarkers have been detected in urine and tissue using a variety of proteomic techniques, each having specific conceptual considerations and technical implications. Promising preclinical data are available for several of these proteins; however, the combination of single urinary proteins into multimarker panels might better encompass the molecular heterogeneity of bladder cancer within this patient population, and prove more effective in clinical use.
UR - http://www.scopus.com/inward/record.url?scp=84930757392&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2015.100
DO - 10.1038/nrurol.2015.100
M3 - Scientific review articles
C2 - 26032553
AN - SCOPUS:84930757392
SN - 1759-4812
VL - 12
SP - 317
EP - 330
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 6
ER -
